Abstract
BackgroundAntimalarial drugs (AMs) namely hydroxychloroquine (HCQ) have been shown to reduce disease activity and prevent flares of patients with systemic lupus erythematosus (SLE).1,2 Despite some evidence highlighting the immunomodulatory properties,2...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
